Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

BACKGROUND: Neoadjuvant chemotherapy (NAC) is a standard treatment for stage II/III breast cancer patients, and response to NAC is a useful prognostic marker. Since its introduction, 6–8 cycles of NAC has become the standard regimen to improve the outcome of these patients. The purpose of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yaewon, Im, Seock-Ah, Keam, Bhumsuk, Lee, Kyung‑Hun, Kim, Tae‑Yong, Suh, Koung Jin, Ryu, Han Suk, Moon, Hyeong-Gon, Han, Sae‑Won, Oh, Do‑Youn, Han, Wonshik, Kim, Tae‑You, Park, In Ae, Noh, Dong-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955253/
https://www.ncbi.nlm.nih.gov/pubmed/27444430
http://dx.doi.org/10.1186/s12885-016-2500-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955253/
https://www.ncbi.nlm.nih.gov/pubmed/27444430
http://dx.doi.org/10.1186/s12885-016-2500-1

Ejemplares similares